Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Ligand Pharmaceuticals Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Our first question comes from Joe Pantginis from Merriman Curhan Ford. Your line is now open. Joe Pantginis – Merriman Curhan Ford Hi guys, how are you? Thanks for taking the call. Couple quick questions if you don’t mind, I guess maybe in the order...
- Earnings calls 2009-05-06
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- As the American Association for the Study of Liver Diseases kicks off its annual confab this week, all eyes will be on efforts to revolutionize the standard of care for hepatitis C...especially now that new data show the standard has unfortunate sexual side effects. by Trista Morrison
- Blog posts 2009-10-27
Additional Resources
- HEPATITIS A & B.(GlaxoSmithKline PLC's Twinrix in treating the disease)(Brief Article)
- HEPATITIS A & B GlaxoSmithKline PLC was granted FDA approval for Twinrix Hepatitis A inactivated and Hepatitis B recombinant vaccine for the ... HEPATITIS A & B GlaxoSmithKline PLC was granted FDA approval for Twinrix Hepatitis A inactivated and Hepatitis B recombinant vaccine...
- Research articles 2001-05-21
- Hepatitis C Caring Ambassadors Program Launches Hepatitis C Awareness 2005 Campaign: 100,000 Letters to Congress
- OREGON CITY, Ore. -- The Hepatitis C Caring Ambassadors Program HCCAP enthusiastically announces the launch the Internet-based Hepatitis C Awareness 2005 Campaign (www.hepcchallenge.org), which coincides with the May observance of National Hepatitis Awareness Month. The campaign is focused on raising hepatitis C awareness in the minds of the general public,...
- Research articles 2005-05-05
- Biostar Pharma Wins Patent for Second Hepatitis B Product
- ChinaBio Today submits: Biostar Pharmaceuticals, Inc. (BSPM.OB) received a China patent for Aoxing Ganbao, an external use TCM treatment for hepatitis B. Biostar already has name recognition in the hepatitis B sector with its flagship product, Xin Aoxing Oleanolic Acid Capsules. Xin Aoxing Oleanolic capsules, which is the only...
- External links 2009-10-14
- Gilead Sciences Announces Initiation of Phase III Clinical Program Evaluating Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Virus
- FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has begun enrolling patients in its Phase III clinical program evaluating the oral antiviral drug tenofovir disoproxil fumarate tenofovir DF for the treatment of chronic hepatitis B. Two Phase III clinical trials (Studies 102 and 103) will...
- Research articles 2005-07-19
- US FDA approves Bristol-Myers' hepatitis B drug.
- Mar. 31--NEW DELHI -- In a breakthrough achievement in tackling hepatitis B, Bristol-Myers Squibb BMS on Wednesday announced receiving the US FDA approval for its new drug -- entecavir -- for treatment of chronic hepatitis B infection in adults. Mar. 31--NEW DELHI -- In...
- Research articles 2005-03-31
- Roche's hepatitis C drug price hits competition. (Breaking News: Roundup).(Brief Article)
- Roche has made another aggressive bid for market share in the chronic hepatitis C segment. Just days after announcing the resolution of its patent dispute with ICN Pharmaceuticals Inc. and Ribapharm Inc. over the hepatitis C treatment ribavirin, Ro Roche has made another aggressive...
- Research articles 2003-01-20
- VA Health Care: Further Efforts Needed to Improve Hepatitis C Testing for At-Risk Veterans.
- GAO-04-106 December 12, 2003 Hepatitis C is a chronic disease caused by a blood-borne virus that can lead to potentially fatal liverrelated conditions. In 2001, GAO reported that the VA missed opportunities to test about 50 percent of veterans identified as at risk for hepatitis C. GAO was...
- Research articles 2004-01-01
- VA Health Care: Improvements Needed in Hepatitis C Disease Management Practices.
- GAO-03-136 January 31, 2003 In 1998, the Department of Veterans Affairs VA launched an initiative to screen and test veterans for hepatitis C--a chronic blood-borne virus that can cause potentially fatal liver-related conditions. Since 2001, GAO has been monitoring VA's hepatitis C program. This year GAO was asked...
- Research articles 2003-04-01
- Hepatitis C Caring Ambassadors Program Dismayed by Oregon Governor Ted Kulongoski's Veto of Hepatitis C Legislation
- OREGON CITY, Ore. -- The Hepatitis C Caring Ambassadors Program HCCAP announced that they had received notification on July 19th from the office of Oregon Governor Ted Kulongoski that he had vetoed hepatitis C legislation overwhelmingly passed by both the Oregon House and Senate. The legislation, HB 2480, would have...
- Research articles 2005-07-20
- GSK Pulls Dominican Hepatitis Risk Ads After Political Pressure
- GlaxoSmithKline has pulled a campaign promoting hepatitis vaccines for travelers to the Dominican Republic following political pressure from the government there, even though DR is a hotspot for hepatitis and travelers really should consider vaccinations before going. The DR government requested the ad be pulled because it...
- Blog posts 2009-02-17
- Bipartisan Hepatitis C Legislation Reintroduced in Both Houses of Congress
- The Hepatitis C Epidemic Control and Prevention Act [SB-1445, HR-2552] has been reintroduced into both Houses of the 110th Congress by Senator Edward Kennedy (D-MA) and Representative Edolphus Towns (D-NY). The Hepatitis C Epidemic Control and Prevention Act mandates a comprehensive federal hepatitis C program to include counseling and...
- Research articles 2007-05-30
- Biota and GlaxoSmithKline finalize hepatitis C agreement. (Markets: Life Sciences).(also mentions Gilead and Ribahparm's hepatitis drugs)(Brief Article)
- GLAXOSMITHKLINE PLC GSK and Biota Holdings Ltd. have finalized a license agreement aimed at developing new drugs for the $2 billion hepatitis C market. For GSK, the deal comes on the heels of a $10 million pact with Gilead Sciences Inc. for hepat GLAXOSMITHKLINE...
- Research articles 2002-08-19
- China's Hepatitis B Market to Double by 2012
- ChinaBio Today submits: The market for hepatitis B drugs in China is expected to grow 135% by 2012, according to a new report from Decision Resources. From $340 million in 2007, sales of hepatitis B treatments will increase to $800 million over the five years, a CAGR of 18%....
- External links 2008-09-01
- New Roche drug given nod in Switzerland for hepatitis B sufferers
- BASEL, Switzerland AFP — Sufferers of the life-threatening disease hepatitis B have a new treatment to hand after Swiss pharmaceutical giant Roche said that Switzerland has approved its Pegasys drug. The green light for the breakthrough treatment will also be a financial boon for the Swiss drug maker as...
- Research articles 2004-12-22
- ABC's of hepatitis, The
- Raymond Koff, M.D., is a professor at the University of Massachusetts Medical School and chair of the Department of Medicine at Metro West Medical Center in Framingham and Natick. Formerly with the Centers for Disease Control and Prevention, he has done extensive research on the spread, prevention, and treatment of...
- Research articles 1995-04-01
- ABCs of hepatitis, The
- Feeling tired and experiencing flu-like symptoms? It may not be the flu at all AT ACHY, RUN-DOWN condition and lack of appetite may be hepatitis, an insidious viral infection that will over time result in cirrhosis or liver cancer. Or worse. You could unknowingly be infected with the most virulent...
- Research articles 1998-03-01
- China's doctors not up to scratch on hepatitis B
- BEIJING AFP — A majority of Chinese doctors do not have adequate knowledge of hepatitis B and how to treat and prevent the life-threatening viral liver infection. A survey found that only two-thirds of 290 doctors specializing in infectious diseases were fully aware of hepatitis treatment procedures, the China...
- Research articles 2005-09-29
- Medistrategies International Promoting Viraguard® Hospital Wipes With New EPA - Approved Label Claims For Hepatitis A, B and C To Medical Group Purchasing Organizations - 3 Contracts Signed
- ST. PETERSBURG, Fla. -- Veridien Corporation (OTCBB:VRDE) announced that its hospital contract development partner, Medistrategies International, is promoting the ViraguardR Hospital Wipes with their new EPA-approved label claims for killing all three of Hepatitis A, B and C, to Medical Group Purchasing Organizations (GPO's). According to the U.S. Centers...
- Research articles 2005-10-31
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
